[HTML][HTML] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
FH Shi, H Li, M Cui, ZL Zhang, ZC Gu… - Frontiers in …, 2018 - frontiersin.org
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
FH Shi, H Li, M Cui, ZL Zhang, ZC Gu… - Frontiers in …, 2018 - europepmc.org
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
[HTML][HTML] Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled …
FH Shi, H Li, M Cui, ZL Zhang, ZC Gu… - Frontiers in …, 2018 - ncbi.nlm.nih.gov
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
FH Shi, H Li, M Cui, ZL Zhang… - Frontiers in …, 2018 - pubmed.ncbi.nlm.nih.gov
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
FH Shi, H Li, M Cui, ZL Zhang, ZC Gu, XY Liu - 2018 - cabidigitallibrary.org
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
FH Shi, H Li, M Cui, ZL Zhang, ZC Gu… - Frontiers in …, 2018 - europepmc.org
Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …